Keywords: Mesenchymal-epithelial transition alteration, Synchronous non-small cell lung cancer, Capmatinib, Targeted therapy Lung cancer represents the leading cause of cancer-related deaths worldwide [1]. There are two main histological subtypes: non-small cell lung cancer (NSCLC) that accounts for roughly 80–85% of all the cases and small cell lung cancer that accounts for 15–20% [2].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile